Abstract
Pulmonary arterial hypertension, categorized as group 1 pulmonary hypertension by the World Health Organization classification system, represents a major complication of systemic sclerosis resulting from pulmonary vascular involvement of the disease. The high mortality seen in systemic sclerosis-associated pulmonary arterial hypertension is likely due to the impairment of right ventricular systolic function and the coexistence of other non-group-1 pulmonary hypertension phenotypes that may negatively impact clinical response to pulmonary arterial hypertension-targeted therapy. This review highlights two areas of recent advances regarding the management of systemic sclerosis patients with pulmonary hypertension: the tolerability of pulmonary arterial hypertension-targeted therapy in the presence of mild to moderate interstitial lung disease and the potential clinical significance of the antifibrotic effect of soluble guanylate cyclase stimulators demonstrated in preclinical studies.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference96 articles.
1. New insights into the pathogenesis of systemic sclerosis.;M Tamby;Autoimmun Rev.,2003
2. Systemic sclerosis: An update.;J Varga;Bull NYU Hosp Jt Dis.,2008
3. Criteria for the classification of early systemic sclerosis.;E LeRoy;J Rheumatol.,2001
4. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being.;T Medsger;Rheum Dis Clin North Am.,2003
5. Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients.;H Poormoghim;Arthritis Rheum.,2000
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献